🏗️ Collaboration, technology, and regulatory support are essential for encouraging development. Lead author Logan Germain emphasizes the need for clear regulations and partnerships to create viable paths for investment.
🌍 Decentralized manufacturing may also help meet local needs effectively.
Introduction:
The article discusses the challenges faced in developing cell and gene therapy (CGT) infrastructure within smaller markets, highlighting the importance of technology, regulatory support, and collaborative efforts to enhance CGT capacity and accessibility.
- Investment in CGT infrastructure is largely influenced by revenue potential, limiting development in smaller markets.
- Collaboration between stakeholders and regulatory support are crucial for bridging the investment gap in CGT.
- Smaller markets often lack clear regulations, further deterring investment in CGT manufacturing.
- Decentralized manufacturing models, such as point-of-care production, may address the needs of smaller markets but require coordinated planning and regulatory guidance.
- Strategic investments and public-private partnerships are essential for fostering innovation and filling funding gaps for CGT startups.
Conclusion:
Developing CGT capacity in smaller markets presents significant challenges that must be addressed through collaborative efforts and strengthened regulatory frameworks. By fostering partnerships and investing in innovative manufacturing solutions, these markets can enhance access to CGT therapies, ultimately benefiting patient populations and driving industry growth.
